Rituximab rituxan

anti-CD56 (B159), anti-CD56 (NCAM-1), anti-CD3 (UCHT1), anti-CD16 (3G8), anti-CD64 (10.1), IgG1 (MOPC21) from Becton Dickinson (BD, CA, USA). Anti-KIR2DL1/DS1 (EB6), anti-KIR2DL2/3/DS2 (GL183) and anti-NKG2A (Z199) from Beckman Coulter (CA, USA). The anti-CD107a (H4A3) from Biolegend (CA, USA). The anti-Lir-1 (HP-F1) from eBioscience (CA, USA). The anti-human IgG4 (HP6025) and Phenylarsine oxide from Sigma Aldrich. The FcγRI (10.1) blocking antibody from R&D Systems (MN, USA). IPH2101 from Innate Pharmaceuticals Inc. (France)/Bristol-Myers Squibb (NY, USA). Rituximab (Rituxan) from Genentech (CA, USA). Human AB serum from Atlanta Biologicals (GA, USA). Human recombinant IFN-γ from Biolegend and human recombinant IL-2 (Proleukin® (Aldesleukin)) from Chiron (CA, USA). Human IvIg (Gammagard) from Baxter International Inc. (IL, USA).

Murine kidney transplantation was performed as described by Zhang and colleagues (21 (link)). Briefly, the kidney with vascular supply and ureter were harvested en bloc and the donor artery and vein were anastomosed to the recipient abdominal aorta and inferior vena cava. Following successful anastomosis, the kidney graft perfused instantly. Urinary reconstruction was performed as described by Han and colleagues (22 (link)). The remaining native kidney was nephrectomized at the time of the transplant so that recipient survival was dependent on the kidney graft. Kidney graft survival was assessed by daily examination of overall animal health and measurement of serum creatinine levels. Renal allograft rejection was diagnosed when the mouse showed signs of illness and the creatinine level was elevated to 70 ~ 100 μmol/l at which time grafts were harvested for histopathology analysis. Allograft recipients were treated intraperitoneally with 250 μg anti-human CD20 mAb (Rituximab/Rituxan, Genentech, San Francisco, CA) or control rat IgG (Sigma-Aldrich, St. Louis, MO).